{"id":40851,"date":"2025-12-08T07:00:00","date_gmt":"2025-12-08T00:00:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=40851"},"modified":"2025-12-08T07:00:00","modified_gmt":"2025-12-08T00:00:00","slug":"respiree-secures-singapore-hsa-approval-for-its-ai-enabled-1bioai-software-to-support-acute-deterioration-detection","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=40851","title":{"rendered":"RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO\u2122AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION"},"content":{"rendered":"

SINGAPORE<\/span><\/span>, Dec. 8, 2025<\/span><\/span> \/PRNewswire\/ — AI\/ML health-tech startup\u00a0Respiree<\/a> has received approval from the Health Sciences Authority (HSA) for its 1Bio\u2122AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare professionals in identifying acute inpatient deterioration using AI-enabled machine learning models. Compared to the current standard of care, 1Bio\u2122AI-Acute delivers significantly higher precision in acute deterioration notifications, resulting in fewer false alerts and more efficient clinical support.<\/p>\n

\n

\"Illustrative <\/a>
Illustrative Marketing logo for 1Bio\u2122AI<\/span><\/p>\n<\/div>\n

The 1Bio\u2122AI-Acute system uses only bedside-recorded vital signs\u2014pulse rate, respiratory rate, oxygen saturation, and systolic blood pressure\u2014to generate a probability score that assists clinicians in determining whether additional monitoring may be required. This score provides an indication of the patient’s general physiological state: the higher the score, the greater the likelihood that the patient may require additional monitoring due to potential acute deterioration.<\/p>\n

WHY IT MATTERS<\/b><\/p>\n

“Current early-warning scores that rely on threshold-based methods often suffer from low precision, leading to a high number of alarms and notifications. Advanced AI-driven machine learning models have the potential to deliver significantly greater precision, reducing unnecessary alerts\/notifications, thus enabling healthcare professionals to better focus their time on delivering quality patient care,” said Dr. Gurpreet Singh<\/span>, CEO and Founder of Respiree.<\/p>\n

The 1Bio\u2122AI-Acute is readily available to healthcare professionals through Respiree’s 1Bio\u2122 platform, which recently received regulatory clearance together with the RS001 wearable device. With this milestone, the 1Bio\u2122AI-Acute toolbox, the 1Bio\u2122platform, and the RS001 wearable are all now approved by HSA.<\/p>\n

With the HSA approval for the 1Bio\u2122AI-Acute toolbox, Respiree is now setting its sights on expanding the 1Bio\u2122AI-Acute regulatory approvals across other APAC and ANZ regions, as well as in the United States<\/span>, in the coming months.<\/p>\n

HSA’s approval of the 1Bio\u2122AI-Acute toolbox\u00a0follows the validation study that was recently peer-reviewed and published in the Mayo Clinic Proceedings<\/a>.<\/p>\n

About Respiree<\/b><\/p>\n

Respiree\u2122 is an AI\/ML health tech company building clinically-validated AI for managing disease progression. Respiree\u2122 products are CE marked and has received regulatory clearances from the Therapeutic Goods Administration and the United States Food and Drug Administration (FDA).<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

SINGAPORE<\/span><\/span>, Dec. 8, 2025<\/span><\/span> \/PRNewswire\/ — AI\/ML health-tech startup\u00a0Respiree<\/a> has received approval from the Health Sciences Authority (HSA) for its 1Bio\u2122AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare professionals in identifying acute inpatient deterioration using AI-enabled machine learning models. Compared to the current standard of care, 1Bio\u2122AI-Acute delivers significantly higher precision in acute deterioration notifications, resulting in fewer false alerts and more efficient clinical support.<\/p>\n

\n

\"Illustrative <\/a>
Illustrative Marketing logo for 1Bio\u2122AI<\/span><\/p>\n<\/div>\n

The 1Bio\u2122AI-Acute system uses only bedside-recorded vital signs\u2014pulse rate, respiratory rate, oxygen saturation, and systolic blood pressure\u2014to generate a probability score that assists clinicians in determining whether additional monitoring may be required. This score provides an indication of the patient’s general physiological state: the higher the score, the greater the likelihood that the patient may require additional monitoring due to potential acute deterioration.<\/p>\n

WHY IT MATTERS<\/b><\/p>\n

“Current early-warning scores that rely on threshold-based methods often suffer from low precision, leading to a high number of alarms and notifications. Advanced AI-driven machine learning models have the potential to deliver significantly greater precision, reducing unnecessary alerts\/notifications, thus enabling healthcare professionals to better focus their time on delivering quality patient care,” said Dr. Gurpreet Singh<\/span>, CEO and Founder of Respiree.<\/p>\n

The 1Bio\u2122AI-Acute is readily available to healthcare professionals through Respiree’s 1Bio\u2122 platform, which recently received regulatory clearance together with the RS001 wearable device. With this milestone, the 1Bio\u2122AI-Acute toolbox, the 1Bio\u2122platform, and the RS001 wearable are all now approved by HSA.<\/p>\n

With the HSA approval for the 1Bio\u2122AI-Acute toolbox, Respiree is now setting its sights on expanding the 1Bio\u2122AI-Acute regulatory approvals across other APAC and ANZ regions, as well as in the United States<\/span>, in the coming months.<\/p>\n

HSA’s approval of the 1Bio\u2122AI-Acute toolbox\u00a0follows the validation study that was recently peer-reviewed and published in the Mayo Clinic Proceedings<\/a>.<\/p>\n

About Respiree<\/b><\/p>\n

Respiree\u2122 is an AI\/ML health tech company building clinically-validated AI for managing disease progression. Respiree\u2122 products are CE marked and has received regulatory clearances from the Therapeutic Goods Administration and the United States Food and Drug Administration (FDA).<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-40851","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/40851","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40851"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/40851\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40851"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40851"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40851"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}